Smith Hayes Advisers’s Quest Diagnostics DGX Stock Holding History

Smith Hayes Advisers’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$732K	Sell	10,250 -8,600	-46%	-$577K	0.15%	166
2015 Q4	$1.34M	Buy	18,850 +250	+1%	+$16.8K	0.28%	100
2015 Q3	$1.14M	Sell	18,600 -250	-1%	-$17.5K	0.25%	114
2015 Q2	$1.37M	Hold	18,850	–	–	0.27%	110
2015 Q1	$1.45M	Buy	18,850 +5,550	+42%	+$397K	0.29%	105
2014 Q4	$892K	Buy	+13,300	New	+$839K	0.19%	141

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Smith Hayes Advisers's DGX Position: Q1 2016 in Review

Smith Hayes Advisers reduced its Quest Diagnostics (DGX) stake by 46% in Q1 2016, selling an estimated $577K and leaving 10,250 shares worth $732K. The position accounts for 0.15% of the portfolio, ranked #166.

Smith Hayes Advisers first reported a position in DGX in Q4 2014 and has held it in 6 quarters since. The position peaked at $1.45M in Q1 2015. 557 funds tracked by Wall St. Rank hold DGX as of Q1 2016.

Smith Hayes Advisers held 10,250 shares of Quest Diagnostics worth $732K as of Q1 2016.
Smith Hayes Advisers sold 8,600 Quest Diagnostics shares in Q1 2016, an estimated $577K.
Quest Diagnostics made up 0.15% of Smith Hayes Advisers's portfolio in Q1 2016, its #166 holding.
Smith Hayes Advisers first reported a position in Quest Diagnostics in Q4 2014 and has held it in 6 quarters since.
Smith Hayes Advisers's Quest Diagnostics position peaked at $1.45M in Q1 2015.
557 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2016.

Based on Smith Hayes Advisers's 13F filing for Q1 2016, filed 16 May 2016.